Want a deeper scan?
Get a guided tour of your organization’s security posture from an UpGuard team member.


This is a preliminary report on BioLineRx’s security posture. If you want in-depth, always up-to-date reports on BioLineRx and millions of other companies, start a free trial today. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.
Get the full report

UpGuard Security Rating

/ 950
This is a 0-950 security rating for BioLineRx. The higher the rating, the more likely BioLineRx has good security practices. For complete visibility of the security posture of BioLineRx, start a free trial of UpGuard.

Company info

Modi'in-Maccabim-Re'ut, Center District, Israel.
Last updated
Last updated
Last updated today

Security report for BioLineRx

BioLineRx, or BioLine, is a publicly traded drug development company that seeks to discover compounds for disease treatment and develop them into commercializable drugs. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
Get the full report
Last updated today

BioLineRx Data Breaches and Security News

Relevant news, breaches and security articles relating to BioLineRx.

More security reports

Compare BioLineRx's security performance with other companies.

Leader in Third Party & Supplier Risk Management Software

See how UpGuard shapes up against other platforms in the market.
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan rating
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.